5.54
0.06%
+0.0034
After Hours:
5.54
Vaccinex Inc stock is currently priced at $5.54, with a 24-hour trading volume of 3,417.
It has seen a +0.06% increased in the last 24 hours and a +14.46% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $5.46 pivot point. If it approaches the $5.62 resistance level, significant changes may occur.
Previous Close:
$5.5366
Open:
$5.2564
24h Volume:
3,417
Market Cap:
$8.78M
Revenue:
-
Net Income/Loss:
$-22.01M
P/E Ratio:
-0.8394
EPS:
-6.6
Net Cash Flow:
$-18.31M
1W Performance:
-3.65%
1M Performance:
+14.46%
6M Performance:
+522.47%
1Y Performance:
+1,321%
Vaccinex Inc Stock (VCNX) Company Profile
Name
Vaccinex Inc
Sector
Industry
Phone
585 271 2700
Address
1895 Mount Hope Avenue, Rochester, NY
Vaccinex Inc Stock (VCNX) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Sep-23-20 | Downgrade | BTIG Research | Buy → Neutral |
Sep-04-18 | Initiated | Ladenburg Thalmann | Buy |
Vaccinex Inc Stock (VCNX) Latest News
Trend Tracker for (VCNX) - Stock Traders Daily
Stock Traders Daily
Vaccinex Reports First Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewswire
GlobeNewswire
Vaccinex Reports First Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire Inc.
Watsco, Inc. (NYSE:WSO) Director John Alexander Macdonald Sells 5334 Shares - Defense World
Defense World
Veracyte, Inc. (NASDAQ:VCYT) Short Interest Update - Defense World
Defense World
Principal Securities Inc. Invests $670000 in iShares MSCI USA Momentum Factor ETF (BATS:MTUM) - Defense World
Defense World
Vaccinex Inc Stock (VCNX) Financials Data
Vaccinex Inc (VCNX) Net Income 2024
VCNX net income (TTM) was -$22.01 million for the quarter ending September 30, 2023, a -13.65% decrease year-over-year.
Vaccinex Inc (VCNX) Cash Flow 2024
VCNX recorded a free cash flow (TTM) of -$18.31 million for the quarter ending September 30, 2023, a +7.17% increase year-over-year.
Vaccinex Inc (VCNX) Earnings per Share 2024
VCNX earnings per share (TTM) was -$85.40 for the quarter ending September 30, 2023, a +20.47% growth year-over-year.
About Vaccinex Inc
Vaccinex, Inc., a clinical-stage biotechnology company, focuses on treating cancer and neurodegenerative disease through the inhibition of semaphorin 4D (SEMA4D). The company's lead drug candidate, pepinemab, blocks SEMA4D, a potent biological effector that prevents immune infiltration into tumors and triggers inflammation in chronic diseases of the brain. Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimer's Disease, with ongoing exploration of potential Phase 3 development in Huntington's disease. It has also developed a proprietary drug discovery platform, ActivMAb that it is leveraging through strategic collaborations, by exploiting its unique capability to select antibodies against multi-pass membrane receptors. Vaccinex, Inc. was incorporated in 2001 and is headquartered in Rochester, New York.
Cap:
|
Volume (24h):